Adenovirus infections of immunocompetent adults are usually mild and resolve without serious sequelae. However, adenovirus infections of immunocompromised patients often develop into life-threatening multi-organ disease. Pediatric hematopoietic transplant patients are especially threatened, with high incidence of infection and high mortality rates. Presently, there is no drug specifically approved by the FDA to treat adenovirus infections; thus there is an urgent need to develop effective antivirals against the virus. Previously, we demonstrated that brincidofovir and valganciclovir were efficacious against lethal intravenous challenge with human type 5 adenovirus in the Syrian hamster model. Here, we tested the in vivo efficacy of the combination of these two drugs and showed that the combination of brincidofovir and valganciclovir is more efficacious than either drug alone, thus potentially allowing decreased patient exposure to the drugs while maintaining antiviral efficacy. As antiviral compounds often have toxic side effects, a decrease in dose or duration of therapy allowed by the combination could also improve tolerability.

具有免疫能力的成年人的腺病毒感染通常是轻度的，并且可以治愈而没有严重的后遗症。但是，免疫受损患者的腺病毒感染通常会发展为威胁生命的多器官疾病。小儿造血移植患者尤其容易受到感染，感染率高，死亡率高。目前，尚无FDA专门批准用于治疗腺病毒感染的药物。因此，迫切需要开发有效的抗病毒药物。以前，我们证明了在叙利亚仓鼠模型中，brincidofovir和valganciclovir可有效抵抗人类5型腺病毒的致死性静脉内攻击。在这里，我们测试了体内两种药物联合使用的疗效，并显示比西多福韦和缬更昔洛韦联合使用比单独使用任何一种药物更有效，因此有可能在保持抗病毒功效的同时减少患者对药物的接触。由于抗病毒化合物通常具有毒性副作用，因此减少联合用药的剂量或持续时间也可以提高耐受性。